Sangamo Therapeutics Inc
NASDAQ:SGMO
Sangamo Therapeutics Inc
Tax Provision
Sangamo Therapeutics Inc
Tax Provision Peer Comparison
Competitive Tax Provision Analysis
Latest Figures & CAGR of Competitors
Company | Tax Provision | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Sangamo Therapeutics Inc
NASDAQ:SGMO
|
Tax Provision
$5.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Tax Provision
-$1.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Tax Provision
-$617m
|
CAGR 3-Years
28%
|
CAGR 5-Years
23%
|
CAGR 10-Years
9%
|
|
Amgen Inc
NASDAQ:AMGN
|
Tax Provision
-$582m
|
CAGR 3-Years
13%
|
CAGR 5-Years
13%
|
CAGR 10-Years
-4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Tax Provision
-$760.2m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-60%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Tax Provision
-$184.2m
|
CAGR 3-Years
22%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
6%
|
See Also
What is Sangamo Therapeutics Inc's Tax Provision?
Tax Provision
5.1m
USD
Based on the financial report for Dec 31, 2023, Sangamo Therapeutics Inc's Tax Provision amounts to 5.1m USD.